<p>2025 年 01 月 21 日- 上午 05:00</p>
<p><strong>公司将推动其专利平台技术在各个行业的货币化</strong></p>
<p>西雅图 --（商业新闻）--Know Labs, Inc.（纽约证券交易所美国：KNW），在射频介电光谱（RFDS）开发和应用方面的先锋领导者，自豪地宣布成立其新的业务部门 Know Labs 技术许可（KTL）。KTL 将以成功的高通技术许可（QTL）框架为模型，专注于将 Know Labs 强大的知识产权（IP）组合授权给企业合作伙伴、学术机构和研究组织，促进创新，加速 RFDS 平台技术在广泛行业及学术和科学生态系统中的应用。</p>
<p>KTL 的推出标志着 Know Labs 战略增长计划中的一个关键里程碑。尽管公司仍然专注于利用 RFDS 进行非侵入性医疗诊断的变革性应用，首要关注血糖监测，但 KTL 将通过使外部合作伙伴能够将 RFDS 技术集成到涵盖工业流程、消费电子、汽车进步和物联网（IoT）网络的应用中，释放额外价值。</p>
<p>“通过创建 KTL，我们正在大胆向前迈出一步，以扩大我们 RFDS 平台的影响力和覆盖面，” Know Labs 首席执行官兼董事长 Ron Erickson 表示。“这一举措不仅将 Know Labs 定位为先进 RF 光谱技术的专利许可领导者，还为医疗诊断以外的行业的协作创新打开了大门。坦率地说，呈现在我们面前的机会的广度和规模需要企业合作伙伴与领先学术研究机构之间开放的合作模式。”</p>
<p>“当我们在 2024 年 5 月宣布成立我们的 Skunkworks，以探索将我们的平台技术应用于非侵入性医疗诊断之外的机会时，” Erickson 说，“我们没有预料到有如此多的第三方对探索我们 RFDS 技术的潜在应用表示兴趣。这促使我们成立 KTL，以规范和简化我们与合作伙伴和研究合作者的合作方式。作为早期示例，我们最近宣布了一项商业化 ‘智能方向盘’ 的计划，用于汽车行业的安全应用，以推动 Know Labs 在汽车医疗物联网传感器方面的领导地位。我们现在看到许多机会，可以将我们的 RFDS 技术作为一种高度敏感的 ‘变化或差异检测器’，在一系列工业流程中具有重要应用。与学术机构和研究组织合作，我们看到商业化我们专利数据收集应用开发平台在临床研究中使用的机会。我们将向我们的许可合作伙伴提供软件开发工具包（SDK）和我们的 RFDS 测试自动化产品工具箱。”</p>
<p>KTL 将以双重重点运作：货币化 Know Labs 的知识产权资产以产生许可收入，并创建 RFDS 技术作为行业标准的广泛采用。这一举措与 Know Labs 致力于为股东创造价值，同时推动解决现实世界挑战的突破性技术的承诺相一致。KTL 是对未请求的内部需求的直接回应。</p>
<p>非关联通知和免责声明</p>
<p>高通及其子公司高通技术许可（QTL）是高通公司的注册商标。Know Labs 与高通公司或其任何子公司或附属机构没有任何关联、合作、授权、认可或以任何方式正式连接。</p>
<p>关于 Know Labs, Inc.</p>
<p>Know Labs, Inc.是一家公开公司，其股票在纽约证券交易所美国交易，股票代码为 “KNW”。该公司的平台技术使用射频光谱技术将电磁能量导向物质或材料，以捕捉独特的分子特征。该技术旨在能够集成到各种可穿戴、移动或台式设备中。公司相信，这项已获得专利和申请专利的技术使得有效识别和监测分析物成为可能，而这些分析物之前只能通过侵入性和/或昂贵且耗时的实验室测试来进行。该技术的首个预期应用之一将是一款作为非侵入性血糖监测仪的产品。该设备旨在为用户提供可获取和负担得起的实时血糖水平信息。该产品在上市前需要获得美国食品药品监督管理局（FDA）的批准。通过 KTL 开发的其他产品可能不需要此类事先的 FDA 批准。</p>
<p>安全港声明</p>
<p>本公告包含根据 1995 年《私人证券诉讼改革法案》及 1933 年《证券法》第 27A 条和 1934 年《证券交易法》第 21E 条的修订版所定义的前瞻性声明。这些声明出现在本公告的多个地方，包括所有非历史事实的声明，涉及 Know Labs, Inc.及其董事或高管的意图、信念或当前预期，具体包括： (i) 融资计划； (ii) 影响其财务状况或经营成果的趋势； (iii) 增长战略和运营战略；以及 (iv) 产品表现。您可以通过使用 “可能”、“将”、“能够”、“应该”、“会”、“计划”、“期望”、“预期”、“继续”、“估计”、“项目”、“打算”、“可能”、“预测”、“可能性”、“潜在” 等词语及其变体来识别这些声明。投资者被提醒，任何此类前瞻性声明并不保证未来的表现，并涉及许多超出 Know Labs, Inc.控制能力的风险和不确定性，实际结果可能因各种因素与前瞻性声明中预测的结果存在重大差异。这些风险和不确定性还包括在公司向美国证券交易委员会提交的文件中讨论的其他风险因素，包括截至 2024 年 9 月 30 日的财政年度的 10-K 表格年报、10-Q 和 8-K 表格，以及我们不时向证券交易委员会提交的其他文件。这些文件可在我们网站投资者关系部分的 SEC 文件部分找到，网址为 www.knowlabs.co。公司提醒读者不要对任何此类前瞻性声明过度依赖，这些声明仅在作出时有效。公司没有义务更新任何前瞻性声明，以反映该声明作出后发生的事件或情况。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTAxMjE5NDY3ODFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTAxMjE5NDY3ODFyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20250121946781/en/</p>
<p>Know Labs, Inc. 联系方式：</p>
<p>投资者关系</p>
<p>电话：206-903-1351</p>
<p>ask@knowlabs.co</p>
<p>来源：Know Labs, Inc.</p>

KNWN

KNWND

USBC

<p>Know Labs, Inc. 已推出一个新的业务部门，Know Labs 技术许可（KTL），旨在通过在各个行业中货币化其专利的射频介电光谱（RFDS）技术。KTL 将把公司的知识产权许可给企业合作伙伴和学术机构，以促进 RFDS 技术的创新和应用。该举措与 Know Labs 的战略增长计划相一致，重点关注医疗诊断以及在消费电子、汽车和物联网等更广泛的应用。首席执行官 Ron Erickson 强调了与外部合作伙伴合作以最大化技术潜力的重要性</p>

<p>01/21/2025 - 05:00 AM</p>
<div class="lb-trans"><p>2025 年 01 月 21 日- 上午 05:00</p>
</div><p><strong>Company to Drive Monetization of its Patented Platform Technology Across Diverse Industries</strong></p>
<div class="lb-trans"><p><strong>公司将推动其专利平台技术在各个行业的货币化</strong></p>
</div><p>SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS), is proud to announce the formation of its new business unit, Know Labs Technology Licensing, (KTL). Modeled after the successful Qualcomm Technology Licensing (QTL) framework, KTL will be dedicated to licensing Know Labs’ robust intellectual property (IP) portfolio to corporate partners, academic institutions and research organizations, fostering innovation and accelerating the adoption of RFDS platform technology across a broad range of industries and the academic and scientific ecosystem.</p>
<div class="lb-trans"><p>西雅图 --（商业新闻）--Know Labs, Inc.（纽约证券交易所美国：KNW），在射频介电光谱（RFDS）开发和应用方面的先锋领导者，自豪地宣布成立其新的业务部门 Know Labs 技术许可（KTL）。KTL 将以成功的高通技术许可（QTL）框架为模型，专注于将 Know Labs 强大的知识产权（IP）组合授权给企业合作伙伴、学术机构和研究组织，促进创新，加速 RFDS 平台技术在广泛行业及学术和科学生态系统中的应用。</p>
</div><p>The launch of KTL represents a pivotal milestone in Know Labs’ strategic growth plan. While the company remains focused on leveraging RFDS for transformative applications in non-invasive medical diagnostics with a first focus on blood glucose monitoring, KTL will unlock additional value by enabling external partners to integrate RFDS technology into applications spanning industrial processes, consumer electronics, automotive advancements, and Internet-of-Things (IoT) networks.</p>
<div class="lb-trans"><p>KTL 的推出标志着 Know Labs 战略增长计划中的一个关键里程碑。尽管公司仍然专注于利用 RFDS 进行非侵入性医疗诊断的变革性应用，首要关注血糖监测，但 KTL 将通过使外部合作伙伴能够将 RFDS 技术集成到涵盖工业流程、消费电子、汽车进步和物联网（IoT）网络的应用中，释放额外价值。</p>
</div><p>“With the creation of KTL, we are taking a bold step forward to amplify the reach and impact of our RFDS platform,” said Ron Erickson, CEO and Chairman at Know Labs. “This initiative not only positions Know Labs as a patent licensing leader in advanced RF spectroscopy technology but also opens the door for collaborative innovation in industries far beyond medical diagnostics. Frankly, the breadth and scale of opportunities presented to us requires an open model of collaboration between corporate partners and leading academic research institutions.”</p>
<div class="lb-trans"><p>“通过创建 KTL，我们正在大胆向前迈出一步，以扩大我们 RFDS 平台的影响力和覆盖面，” Know Labs 首席执行官兼董事长 Ron Erickson 表示。“这一举措不仅将 Know Labs 定位为先进 RF 光谱技术的专利许可领导者，还为医疗诊断以外的行业的协作创新打开了大门。坦率地说，呈现在我们面前的机会的广度和规模需要企业合作伙伴与领先学术研究机构之间开放的合作模式。”</p>
</div><p>“When we announced the formation of our Skunkworks in May 2024, to explore opportunities to leverage our platform technology beyond non-invasive medical diagnostics,” said Erickson, “we didn’t expect the large number of third parties expressing interest in exploring potential applications for our RFDS technology. This prompted our formation of KTL to codify and streamline our approach to working with partners and research collaborators. As an early example, we recently announced a program to commercialize a ‘smart steering wheel’ for safety applications in the automotive industry to advance Know Labs’ leadership in automotive medical IoT sensors. We now see a number of opportunities to leverage our RFDS technology as a highly sensitive ‘change or difference detector,’ with important applications in a range of industrial processes. Working with academic institutions and research organizations, we see opportunities to commercialize our patented data collection application development platform for use in clinical research. We will provide Software Development Kits (SDKs) and our toolbox of RFDS test automation products to our licensing partners.”</p>
<div class="lb-trans"><p>“当我们在 2024 年 5 月宣布成立我们的 Skunkworks，以探索将我们的平台技术应用于非侵入性医疗诊断之外的机会时，” Erickson 说，“我们没有预料到有如此多的第三方对探索我们 RFDS 技术的潜在应用表示兴趣。这促使我们成立 KTL，以规范和简化我们与合作伙伴和研究合作者的合作方式。作为早期示例，我们最近宣布了一项商业化 ‘智能方向盘’ 的计划，用于汽车行业的安全应用，以推动 Know Labs 在汽车医疗物联网传感器方面的领导地位。我们现在看到许多机会，可以将我们的 RFDS 技术作为一种高度敏感的 ‘变化或差异检测器’，在一系列工业流程中具有重要应用。与学术机构和研究组织合作，我们看到商业化我们专利数据收集应用开发平台在临床研究中使用的机会。我们将向我们的许可合作伙伴提供软件开发工具包（SDK）和我们的 RFDS 测试自动化产品工具箱。”</p>
</div><p>KTL will operate with a dual focus: monetizing Know Labs’ IP assets to generate licensing revenues and creating widespread adoption of RFDS technology as an industry standard. This move aligns with Know Labs’ commitment to delivering shareholder value while advancing groundbreaking technology that addresses real-world challenges. KTL is a direct response to unsolicited inbound demand.</p>
<div class="lb-trans"><p>KTL 将以双重重点运作：货币化 Know Labs 的知识产权资产以产生许可收入，并创建 RFDS 技术作为行业标准的广泛采用。这一举措与 Know Labs 致力于为股东创造价值，同时推动解决现实世界挑战的突破性技术的承诺相一致。KTL 是对未请求的内部需求的直接回应。</p>
</div><p>Notice of Non-Affiliation and Disclaimer</p>
<div class="lb-trans"><p>非关联通知和免责声明</p>
</div><p>Qualcomm, and its subsidiary Qualcomm Technology Licensing (QTL), are registered trademarks of Qualcomm, Inc. Know Labs is not affiliated, associated, authorized, endorsed by, or in any way officially connected with Qualcomm, Inc., or any of its subsidiaries or its affiliates.</p>
<div class="lb-trans"><p>高通及其子公司高通技术许可（QTL）是高通公司的注册商标。Know Labs 与高通公司或其任何子公司或附属机构没有任何关联、合作、授权、认可或以任何方式正式连接。</p>
</div><p>About Know Labs, Inc.</p>
<div class="lb-trans"><p>关于 Know Labs, Inc.</p>
</div><p>Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses radio frequency spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile or bench-top form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. Among the Company’s first expected applications of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration (FDA) clearance prior to its introduction to the market. Other products, developed through KTL may not require such prior FDA approval.</p>
<div class="lb-trans"><p>Know Labs, Inc.是一家公开公司，其股票在纽约证券交易所美国交易，股票代码为 “KNW”。该公司的平台技术使用射频光谱技术将电磁能量导向物质或材料，以捕捉独特的分子特征。该技术旨在能够集成到各种可穿戴、移动或台式设备中。公司相信，这项已获得专利和申请专利的技术使得有效识别和监测分析物成为可能，而这些分析物之前只能通过侵入性和/或昂贵且耗时的实验室测试来进行。该技术的首个预期应用之一将是一款作为非侵入性血糖监测仪的产品。该设备旨在为用户提供可获取和负担得起的实时血糖水平信息。该产品在上市前需要获得美国食品药品监督管理局（FDA）的批准。通过 KTL 开发的其他产品可能不需要此类事先的 FDA 批准。</p>
</div><p>Safe Harbor Statement</p>
<div class="lb-trans"><p>安全港声明</p>
</div><p>This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2024, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.</p>
<div class="lb-trans"><p>本公告包含根据 1995 年《私人证券诉讼改革法案》及 1933 年《证券法》第 27A 条和 1934 年《证券交易法》第 21E 条的修订版所定义的前瞻性声明。这些声明出现在本公告的多个地方，包括所有非历史事实的声明，涉及 Know Labs, Inc.及其董事或高管的意图、信念或当前预期，具体包括： (i) 融资计划； (ii) 影响其财务状况或经营成果的趋势； (iii) 增长战略和运营战略；以及 (iv) 产品表现。您可以通过使用 “可能”、“将”、“能够”、“应该”、“会”、“计划”、“期望”、“预期”、“继续”、“估计”、“项目”、“打算”、“可能”、“预测”、“可能性”、“潜在” 等词语及其变体来识别这些声明。投资者被提醒，任何此类前瞻性声明并不保证未来的表现，并涉及许多超出 Know Labs, Inc.控制能力的风险和不确定性，实际结果可能因各种因素与前瞻性声明中预测的结果存在重大差异。这些风险和不确定性还包括在公司向美国证券交易委员会提交的文件中讨论的其他风险因素，包括截至 2024 年 9 月 30 日的财政年度的 10-K 表格年报、10-Q 和 8-K 表格，以及我们不时向证券交易委员会提交的其他文件。这些文件可在我们网站投资者关系部分的 SEC 文件部分找到，网址为 www.knowlabs.co。公司提醒读者不要对任何此类前瞻性声明过度依赖，这些声明仅在作出时有效。公司没有义务更新任何前瞻性声明，以反映该声明作出后发生的事件或情况。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTAxMjE5NDY3ODFyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250121946781r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20250121946781/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20250121946781/en/</p>
</div><p>Know Labs, Inc. Contact:</p>
<div class="lb-trans"><p>Know Labs, Inc. 联系方式：</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>T: 206-903-1351</p>
<div class="lb-trans"><p>电话：206-903-1351</p>
</div><p>ask@knowlabs.co</p>
<div class="lb-trans"><p>ask@knowlabs.co</p>
</div><p>Source: Know Labs, Inc.</p>
<div class="lb-trans"><p>来源：Know Labs, Inc.</p>
</div>

Know Labs 推出 Know Labs 技术许可（KTL）| KNW 股票新闻